

## Index

---

Note: page numbers in *italics* refer to figures and tables

adaptive responses during development 35–7  
 S-adenosylmethionine (SAM) 69  
 adipocytes, maternal protein restriction 247–8  
 adipocytokines 437  
 adipogenesis, fetal 159  
 adiponectin 211  
     metabolic syndrome 437  
 adipose tissue  
     function of fetal 256–7  
     stores in pregnancy 162–3  
     mobilisation 163–4  
 adiposity  
     body mass index 436–7  
     early growth 267  
     gain in childhood 466–7  
     maternal nutrient restriction 257, 259  
 adiposity rebound 3  
     adult disease risk 226–8  
     diabetes type 2 18, 18, 226–7, 228  
     obesity 18  
 adolescence, pregnancy 465  
 adrenal cortex 193–4  
 adrenocortical function, hypoxia 185–6  
 adrenocorticotrophic hormone (ACTH)  
     adrenal cortex response 194  
     fetal fat 257–8  
     hypoxic response 185–6  
     pituitary function 193  
 adrenocorticotrophic hormone (ACTH) receptors  
     194  
 age, gestational  
     breast cancer risk 418  
     testicular cancer 420  
 age, maternal and breast cancer 416–17

- ageing 426–32
  - calorie restriction 431
  - causes 426–9
  - DNA damage 428–9
  - mechanisms 426
    - cellular 428–9
    - molecular 428–9
  - musculoskeletal system 392–3
  - natural selection 427
  - normal 427–8
  - plasticity 430–2
  - reactive oxygen species 428–9
  - social insects 431–2
  - telomere damage 428–9
- age-related disease 427–8
- agouti viable yellow (*A<sup>vy</sup>*) allele 69
- airway
  - chronic obstructive airways disease 19
  - function 361–2
  - growth 19
    - fetal growth restriction 339–40
    - maternal smoking 340–1
  - remodelling 360–1
  - structure 361–2
    - environmental factors 362–3
- allergens
  - avoidance 355
  - exposure
    - allergic disease 357
    - pregnancy 354–5
- allergic immune response 350–1
  - postnatal influences 356–7
- allergic inflammation, genetic polymorphisms 361–2
- allergic sensitisation 349–50
- allergy/allergic disease 349–64
  - allergen exposure 357
  - epidemiology 350
  - genetic polymorphisms 351–2
  - head circumference 356
  - hygiene hypothesis 358, 358–60
  - incidence 350
- alveoli
  - formation 2, 3
    - undernutrition 339
  - growth 19
- Alzheimer's disease, ageing 428
- amino acid transporters, system A 135–6, 150
  - imprinted genes 138
- amino acids
  - embryo metabolism 54–5
  - fetal metabolism 144–5
  - pancreas development 236–7
  - placental transport 135–6
- anaemia
  - fetal 278–9
  - iron maternal supplementation 111–12
  - kidney disease 316
- androgens, female exposure 85
- angiogenesis, placental 134–5
- angiogenic factors, placental 134
- angiotensin II
  - body fluid regulation 324, 327, 328
  - metabolic syndrome 437
- angiotensin receptors 318, 328, 329–30
- angiotensinogen 437
- animal studies 2
- anthropometry, maternal
  - fetal growth association 104–6
  - fetal outcomes 101–2
- indicators
  - IUGR 102–3
    - low birthweight 101–2, 104
    - preterm delivery 102, 103–4
  - pregnancy outcome 104
- antibiotics, use in pregnancy 358
- antigen-presenting cells
  - allergic immune response 351
  - fetal 353
- antioxidants 355
- anxiety in pregnancy 195–6
- aorta, elasticity 294
- aquaporins 312–13
- arachidonic acid 164, 166
  - preterm infant formula supplementation 170
- arginine vasopressin 323
  - ACTH stimulation 193
  - body fluid regulation 324
  - fetal secretion 325
  - neurons 192–3
  - osmoregulation programming 326–8
- arteries
  - elastin 14
  - oxidation-sensitive mechanisms in wall 304
- asthma 19–20, 349–50
  - airway remodelling 360–1
  - allergic sensitisation 349–50
  - associated factors 363

## 498 Index

- asthma (*cont.*)
  - bronchial hyper-responsiveness 361–2
  - infant feeding allergy 360
  - obesity 363
  - prevalence 349, 350, 350
- atherogenesis 300–6
  - arterial gene expression 303
  - maternal hypercholesterolaemia 300–1, 304–6
    - fetal lesion formation 301–4
  - nitric oxide 303
  - oxidation 301–2
  - vascular endothelial dysfunction 300
- atherosclerosis
  - hypertension association 306
  - low birthweight association 306
  - management 443
  - myocardial infarction 300
  - vascular disease risk 437
- atopy 19–20
  - PUFA association 170–1
- atrazine 84
- autism 379
- autoimmune effects, environmental chemicals
  - 92–3
- autonomy of women 474
- baroreceptor responses
  - sympathetic nervous system 329
  - vascular endothelial dysfunction 294–5
- behaviour 370–6
  - nutrition 371–5
  - stress in pregnancy 373–4
- behavioural dysfunction
  - environmental chemicals 91–2
  - maternal iron restriction 248
  - stress 269
  - very low birthweight 371
- behavioural programming 270
- beta cells 233–5
  - diabetes type 1 240
  - diabetes type 2 238–9
  - early malnutrition 235–8
  - fetal programming 237–8
  - function 235
- betamethasone, HPA axis 197–8
- birth, size at 223–4
  - coronary heart disease 7–8
  - developing countries 458–9
  - diabetes type 2 16, 458–61
  - disease association 450
  - fetal programming 473
  - glucose maternal levels 461
  - glucose-sparing muscle metabolism 17
  - high 459–61
  - hypertension 458–61
  - insulin resistance 17
  - maternal birthweight 22–3, 465
  - maternal factors 465
  - proportions 8
  - small and children growing big 458–9
  - vascular compliance 290
  - see also* intrauterine growth retardation (IUGR); small for gestational age (SGA)
- birth order, testicular cancer 420
- birthweight
  - bone mineral content 402
  - breast cancer risk 416, 417
  - caloric maternal supplementation 119–20
  - cardiovascular disease 275, 458
  - cognitive function 370–1
  - coronary heart disease 10
  - depression association 371
  - diabetes
    - maternal 460–1
    - type 2 458–61
  - fat accumulation 159–60
  - glucose intolerance 206–7
  - grip strength 401
  - high 459–61
  - high-altitude studies 184
  - hypertension 458–61
  - maternal 22–3
    - blood pressure of offspring 23
    - intergenerational influences 120–1
  - metabolic syndrome 266
  - muscle mass 403
  - placental size 11–13
  - prostate cancer 420–1
  - testicular cancer 420
  - twins 216–17
  - vascular compliance 290
  - see also* low birthweight
- bisphenol A 84
  - obesity association 88–9
  - prostate effects 86
- blastocyst inner cell mass (ICM) 54, 56
- DNA methylation 66

- blood clotting 15
- blood pressure 12, 10–12, 14
  - breastfeeding 451
  - control 261
  - fetal programming 440
  - impaired PUFA assimilation 168–9
  - infant nutrition 451
  - maternal birthweight 23
  - maternal nutrition
    - protein intake 24
    - restriction 260
  - maternal nutritional status 466
  - see also* hypertension
- body composition
  - maternal 24–5
  - metabolic syndrome 269–70
- body mass index (BMI) 227
  - accelerated 466–7
  - adiposity 436–7
  - cardiovascular disease 452, 452
  - children 18
  - infant 18
  - maternal 24–5
    - pre-pregnancy 104
    - pre-pregnancy and preterm delivery 105
  - maternal nutrition 101
- body size, maternal undernutrition 400–1
- body weight
  - infants
    - adult bone mass 395–6
    - gain 463–4
  - maternal 101
    - components of gain 105–6
    - gain in pregnancy 105
    - pre-pregnancy 102–4, 105
  - rapid weight gain prevention in children 25
  - see also* birthweight
- bonding behaviour 374
- bone
  - growth in utero 393–4
  - growth plate
    - chondrocytes 411–12
    - fetal programming 410–12
    - height 410–11
    - structure in maternal protein deficiency 6, 409–12
  - loss 392–3
  - maturation delay 409
  - nutrition role in development 406–7
- bone marrow
  - rat stromal cells with maternal protein deficiency 407–9
  - total colony number 408
- bone mass 18–19
  - adult and infant body weight 395–6
  - peak 393
- bone mineral accrual in infancy/childhood 394
- bone mineral density (BMD)
  - adult with maternal protein deficiency 412
  - birthweight 402
  - cortisol levels 396–7
  - growth hormone levels 397, 396–7
  - neonatal
    - maternal lifestyle/nutrition 398, 397–8, 399
    - maternal smoking 399
  - protein deprivation 409
  - vitamin D receptor 396
    - genotype 396
- brain
  - damage
    - infection/inflammation models 384–5
    - prenatal 384–6
  - development with placental insufficiency 4
  - factors affecting normal development 380–1
  - function alteration in prenatal compromise 386–7
  - growth 20
  - hypoxia 380
  - hypoxic–ischaemic injury 380
    - acute insults in early gestation 382–3
    - acute insults in late gestation 383
    - chronic insults 383
    - lipopolysaccharide 384–5
    - models 382–3
  - inflammatory agents 4
  - maternal infection/inflammation 381
  - prematurity 5
- breast cancer 415–19
  - birthweight 416, 417
  - breast size perinatal determination 418–19
  - diethylstilbestrol exposure 418
  - oestrogen exposure 416, 417, 418
  - gestational age 418
  - incidence 415–16
  - intrauterine environment 416
  - maternal age 416–17
  - mechanisms 421–2
  - neonatal jaundice 418
  - parity 416–17
  - perinatal characteristics 421

- breast cancer (*cont.*)
  - pre-eclampsia 417
  - preterm birth 418
  - smoking 418
  - twinning 417–18
- breast-feeding 464
  - blood pressure 451
- breasts, size 418–19
- breathing movements, fetal 338
- Brenner hypothesis of hypertension 313–14
- bronchial hyper-responsiveness 361
  - asthma 361–2
- bronchopulmonary dysplasia 343
- calcium
  - fetal accumulation 394
  - maternal supplementation 111, 116
- calcium ions 384
- calorie restriction, ageing 431
- cancer
  - diethylstilbestrol association 83–5
  - DNA methylation 71
  - early origins 415–22
  - epigenetics 71–2
  - mammary gland developmental delay 84
  - oestrogenic environmental chemicals 84–5
  - tumour-suppressor gene silencing 71–2
- carboxaloxone 249
- cardiac anatomy 279–80
- cardiovascular disease
  - adiposity rebound 226–7
  - aetiology 276
  - birthweight 275, 458
  - body mass index 452, 452
  - childhood growth 225–6
  - chronic 436–7
  - C-reactive protein levels 270–1
  - developing countries 457
  - diabetes 437
  - early life environment 438–9
  - epidemiology 275–6
  - epigenetic effects 438–9
  - fetal hypoxia 180–2, 277–8
  - fetal nutrition 276–7
  - fetal origins 223
  - genetic risks 276
  - hazard ratios 224
  - hypertension 437
  - infant growth 224–5, 463–4
  - infant weight gain 463–4
  - IUGR 178–9
  - management 442–3
  - maternal nutrition 465–6
  - postnatal pathways 282
  - prenatal environment 276
  - risk factors 275–6
    - transgenerational transmission 292
  - risk in South Asians 267
  - susceptibility 438
  - see also* coronary heart disease
- cardiovascular system
  - afterload 280–1
  - cardiac loading conditions 280–1
  - defence in prenatal hypoxia 179–83
  - dysfunction 187
  - endothelial dysfunction 281–2
  - fetal anaemia 278–9
  - fetal influences on structure/function 14–15
  - homeostasis 286, 287
  - programming 275–83
    - fetal nutrition 276–7
    - glucocorticoids 277
  - shear forces 279
- carotid atherosclerosis 11
- carotid chemoreceptors 180
- causality 448–9
- CD14 359
- central nervous system, impaired PUFA assimilation 166–8
- cerebral hypoxia 380
  - see also* brain, hypoxic–ischaemic injury
- cerebral palsy 379, 381
  - intrauterine inflammation with fetal asphyxia 381
- chemotherapy, epigenetic 71–2
- children
  - body mass index 18
  - bone mineral accrual 394
  - cardiovascular disease pathways 282
  - growth 6–7
    - cardiovascular disease risk 225–6
    - coronary heart disease 8–9
    - height 464
    - hip fracture 399–400, 400
    - rapid weight gain prevention 25
    - see also* infants; neonates
- chlordan 92
- chlorpyrifos 91

- cholesterol
  - fetal development 160
  - lowering in maternal hypercholesterolaemia 306
  - maternal 304
  - placental transport 165–6
  - serum levels 15
- cholesteryl ester 161–2
- chondrocytes 393–4
  - growth plate 411–12
  - zones 409–10
- chromatin
  - epigenetic information 63–5
  - remodelling 64, 93
- chronic obstructive airways disease 19
- Clara cell protein 16 (CC16) gene 362
- clinical studies in public health 451
- cloning 67–8
  - genetic manipulation potential 68
- cognitive dysfunction
  - docosahexaenoic acid levels 167–8
  - environmental chemicals 91–2
  - fetal growth 167–8
  - glucocorticoid fetal administration 198–9
- cognitive function 20, 370–6
  - birthweight 370–1
  - brain growth 20
  - nutrition 371–5
- cohort studies in public health 447–8, 450
- colony-forming unit-fibroblastic (CFU-F) 400, 407–9
  - bone marrow 408
- conceptus
  - epigenetic state 43–4
  - genomic state 43–4
- contraception 4
- coronary artery function 282
- coronary bed conductance 279
  - fetal anaemia 278–9
- coronary heart disease
  - birthweight 10
  - childhood growth 8–9
  - developing countries 457
  - early/adult environment interactions 10
  - fetal development 6–7
  - fetal growth 8
  - growth 10, 226
  - hazard ratio 9, 225
  - infant growth 8–9
  - magnitude of growth effect 9–10
  - management 443
  - mortality 7
  - placental weight 8
  - prenatal events 1–2
  - risk 3
    - with low birthweight 6
  - size at birth 7–8
- corticosteroid receptors 192, 196
- corticotrophin-releasing hormone (CRH)
  - ACTH stimulation 193
  - neurons 178, 192–3
- cortisol
  - bone mineral density 396–7
  - fetal fat 257–8
  - metabolic syndrome 438
  - plasma levels 149
  - stress and low birthweight 269
- CpG dinucleotides 62, 63, 93
- CpG oligonucleotides, bacterial 359
- C-reactive protein (CRP)
  - coronary heart disease risk 270–1
  - endothelial activation 289
  - pregnancy 271
- cretinism, iodine maternal supplementation 122
- cryptorchidism 419
- cytokines
  - in-utero exposure 251
  - pregnancy 271
  - proinflammatory 381
- daf* genes 430
- degenerative disease
  - epidemiology 6
  - prevention 25–6
- dehydroepiandrosterone (DHEA) 194
  - SGA children 212
- depression, birthweight association 371
- developing countries 456–68
  - cardiovascular disease 457
  - coronary heart disease 457
  - diabetes type 2 457, 461
  - height growth in children 464
  - IUGR 456, 457
  - low birthweight 458–9
  - maternal nutrition 464–6
  - nutrition 456–7
  - obesity 467
  - public health policy 466–7
- developmental origins of health and disease (DOHaD) 1–4
  - conceptual framework 21

- developmental plasticity 33, 34–5, 37
  - critical windows 34
  - embryo 51–3
  - environmental cues 34
  - environmental factors 4
    - pathological 34–5
  - growth patterns and disease 229
  - model 43
  - osteoporosis 400–1
  - time limitation 34
- developmental programming *see* fetal programming
- dexamethasone
  - HPA axis 197–8
  - treatment in pregnancy 249
    - hypertension in offspring 277
  - very-low-birthweight children 213
- diabetes, maternal
  - birthweight 460–1
  - hyperglycaemia 135
  - intrauterine exposure 239
  - kidney disease 315–16
  - pancreas development 237
- diabetes type 1
  - $\beta$  cells 240
  - cardiovascular disease 437
  - susceptibility with early malnutrition 240
- diabetes type 2 3
  - adiposity rebound 18, 18, 226–7, 228
  - $\beta$  cells 238–9
  - birth size 16, 458–61
    - SGA children 209–11
  - developing countries 457, 461
  - early malnutrition 238–9
  - endothelial dysfunction 288
  - growth
    - patterns 228–9
    - rate 460
  - high fat feeding 251
  - insulin deficiency/resistance 16
  - management 443
  - maternal protein restriction 245
  - metabolic syndrome 441
  - PPAR $\gamma$  gene association 229–30, 230
  - prenatal events 1–2
  - primary prevention 441
  - risk
    - with low birthweight 6
    - in South Asians 267
  - SGA children 209–11
- diet, maternal 106–7
  - fatty acid composition 169–70
  - fetal growth 477
  - macro-/micro-nutrient intervention studies 107–16
- diethylstilbestrol (DES) 83–5
  - breast cancer risk 418
  - immune effects 92–3
  - in-utero exposure 415, 418
  - obesity association 88, 89
  - prostate effects 86
  - testis function 86
- dioxins 84
  - immune effects 92
  - prostate development 85–6
- dipsogenic mechanisms, fetal 324–5
  - programming 325–8
- disability-adjusted life years (DALYs) 449–50
- disease
  - adiposity rebound 226–8
  - adult
    - developmental origins 37–8
    - low birthweight 6
    - susceptibility 10
  - age-related 427–8
  - biological causes 475
  - chronic 3
  - DNA methylation defects 70
  - epigenetics 62, 70–2
  - fetal/postnatal growth relationship 123
  - fetal programming 130
  - growth patterns 228–9
  - histone modification defects 70–1
  - infant growth 224–5, 450
  - mitochondrial dysfunction 76–7
  - nucleosome remodelling defects 70–1
  - placental changes 130
  - poverty association 478
  - prevention strategies 477
  - social causes 475
- disintegrin and metallo-proteinase-33 (ADAM-33) 362
- disposable soma theory 427
- DNA
  - damage with ageing 428–9
  - repair capacity 429–30
- mtDNA 75–6, 429
- DNA methylation 2–3, 62–3, 93
  - aberrant patterns 68
  - cancer 71

- defects 70
- differently methylated region (DMR) 66–7, 70
- gene expression regulation 63
- imprinting 67, 153
- patterns 65–6
- X-inactivation 67
- DNA methyltransferase enzymes (DNMTs) 62–3
- Dnmt3 family 66–7
- docosahexaenoic acid (DHA) 159–60, 164, 165, 166
  - accretion in infants 167
  - brain content 166–8
  - neural development 168
  - neurological function 168
  - preterm infant formula supplementation 170
  - synthesis 165
- Dutch famine 24
  - intergenerational influences 120–1
  - intrauterine influences in mood disorders 20
  - offspring effects 24
  - risk factor programming/induction 223–4
- duty to be well 475–6
- dyslipidaemia 438
  - metabolic syndrome 441
- elastin 14, 294
- electrolyte homeostasis 323–31
  - pregnancy 323–4
- embryo
  - developmental plasticity 51–3
  - developmental potential 55
  - environment 51–2, 52, 53
    - cellular proliferation 56
    - sensitivity to 22
  - environmental sensitivity 51–3
  - epigenesis 53
  - gene expression changes 55–6
  - metabolism 53–5
    - amino acids 54–5
    - hyperglycaemia 53–4
  - plasticity 56–7
- endothelial dysfunction 282
  - catch-up growth 289
  - low birthweight 288–9
  - maternal protein restriction 292
- endothelium *see* vascular endothelium
- endotoxaemia, maternal 251
- endotoxins, exposure 359
- energy
  - intake and obesity 442
  - maternal supplementation 116, 121
  - nutrition mismatch 46–7
  - restriction in pregnancy 110
  - supplementation in pregnancy 108–9
- environment
  - adverse effects on embryo metabolism 53–5
  - embryo 52
    - cellular proliferation 56
    - gene expression changes 55–6
  - epigenetic modification influence 68–9
  - fetal/neonatal mismatch 41
  - genetic influence interactions 10
- environmental chemicals
  - altered programming with in-utero exposure 93–4
  - autoimmune effects 92–3
  - behavioural dysfunction 91–2
  - cognitive dysfunction 91–2
  - developmental programming aberrations 82–3
  - epigenetics 93–4
  - exposure 82–3
  - immune effects 92–3
  - in-utero exposure 82–3
  - nervous system disease/dysfunction 89–92
  - neurodegenerative disease 89–91
  - obesity 88–9
  - pathophysiology 82–3
  - reproductive toxicity
    - female effects 83–5
    - male effects 85–7
- environmental cues, developmental plasticity 34
- environmental factors
  - airway structure 362–3
  - antenatal immune response 354–6
  - developmental plasticity 4
  - fetal programming 475
  - mtDNA sensitivity 77–8
- epialleles, metastable 66
- epigenesis, embryo 53
- epigenetic chemotherapy 71–2
- epigenetic factors
  - behavioural response to stress 374
  - cardiovascular disease 438–9
  - cloning technology 68
- epigenetic information 62–5
  - chromatin 63–5
- epigenetic markers, somatic 68
- epigenetic marks 66



## 504 Index

- epigenetic mechanisms 62
- epigenetic modifications, environmental influence 68–9
- epigenetics 2–3
  - cancer 71–2
  - disease 70–2
  - environmental chemicals 93–4
  - gene activity regulation 93
  - nuclear cloning 67–8
  - parental imprinting 66–7
  - signals 65–6
  - X chromosome inactivation 67
- epilepsy 379
- ethics
  - human research 476–7
  - nutritional supplementation 478
  - public health 478–9
- Eve theory of evolution 78–9
- evolutionary developmental biology 1–2
  
- family size 4
- fat
  - accumulation and birthweight 159–60
  - dietary 251
  - fetal nutritional regulation 257–8
  - fetal programming 258
  - maternal feeding 291–2
    - endothelial dysfunction 293
  - postnatal growth 258–9
  - thermoregulation role in neonates 256
- fatty acids
  - circulating 161–2
  - fetal
    - immune system development 169
    - storage 159–60
    - supply 163–4, 165
  - immune ontogeny 355–6
  - maternal adipose stores 163–4
  - mother as source for fetal tissues 161
  - non-esterified 166, 256
  - oxidation 438
  - placental transport 136, 165–6
  - pools 162
  - release in pregnancy 163
  - tissue development 160
- fertilisation, phenotype alteration after 78
- fertility
  - oestrogens 86–7
  - testicular cancer 420
- fetal development
  - cholesterol 160
  - coronary heart disease 6–7
  - disruption 34–5, 37
    - see also* developmental plasticity
  - fetal origins of adult disease (FOAD) 1
  - fetal programming 395
    - Barker hypothesis 472
  - behavioural 270
  - benefits 472–3
  - blood pressure 440
  - bone growth plate 409, 410–12
  - cardiovascular system 275–83
  - dipsogenic mechanisms 325–8
  - disease prevention strategies 477
  - endocrine 269
  - environment 475
  - environmental chemical-induced aberrations
    - 82–3
  - fat development 258
  - harm 472–3
  - Igf* genes 153
  - induction mechanisms 401
  - intrauterine 147–9
  - kidney 329–30
  - lipid peroxidation 303
  - liver 440
  - maternal nutrition 466
  - metabolic 147–9
  - mitochondrial component 75–9
  - molecular hypothesis 75–6
  - mother relationship with fetus 473–4
  - mtDNA 78–9
  - nephron number 440
  - obesity 255–6, 439–40, 466
  - osmoregulatory mechanisms 325–8
  - osteoporosis 395–401
  - pancreas 440
  - placenta 130, 131, 131, 132, 134–5, 136–8
    - critical periods 139
  - potential of concept 475
  - renal body fluids 440
  - renin–angiotensin system 328, 329–30
  - role of mother 473–4
  - size at birth 473
  - skeleton 407–12
  - socioeconomic factors 473
  - susceptibility during growth 400–1
  - sympathetic nervous system 328–9
  - vascular function 290–5
- fetal salvage hypothesis 209

- fetus
- afterload 280–1
  - APCs in gut 353
  - breathing movements 338
  - calcium accumulation 394
  - cardiac anatomy 279–80
  - cardiac loading conditions 280
  - cardiovascular structure/function 14–15
  - dipsogenic mechanisms 324–5
  - endocrine gland development 150–1
  - environment
    - mismatch with neonatal 41
    - prediction of subsequent 6
  - fuel reserve development 151
  - hypothalamic–pituitary–adrenal axis 13–14
  - hypotonicity 324
  - immune response 352
  - lipids in development 159–60
  - metabolic syndrome influences 267–8
  - osmoregulatory mechanisms 324–5
  - outcomes and maternal anthropometry
    - 101–2
  - phenotype and health consequences 46
  - physiology 56–7
  - protection 474
  - relationship with mother 473–4
  - rights 474
  - skeletal development 393
  - supply line 118
  - surrogates for adaptations 2
  - swallowing 324–5, 353
  - undernutrition in twins 217
  - see also* growth, fetal; nutrition, fetal
- fish oil, maternal supplementation 113–14
- fluid homeostasis 323–31
- pregnancy 323–4
- fluid regulation 324–5
- folate
- maternal supplementation 112–13, 122
  - iron combination 113
  - periconceptual 112–13
- food
- intake in obesity 442
  - security 436
  - see also* nutrition
- fractures, osteoporotic 392–3, 395–401
- gene expression
- environmental response changes in embryo 55–6
  - regulation by DNA methylation 63
- gene–environment interactions 2–3, 39–40
- early life 229–30
  - genetic polymorphisms 38–9
- genes
- epigenetic regulation of activity 93
  - silencing 93
- genes, imprinted
- methylation status 53
  - placental 138
  - placental development 153
- genetic imprinting 66–7, 93
- genetic influences, environmental interactions
  - 10
- genetic polymorphisms
- allergic inflammation 361–2
  - allergy 351–2
  - gene–environment interactions 38–9
- genistein 84–5
- obesity 88, 89
- genome, epigenetic modification 41
- genomic imprinting 153
- ghrelin 55
- Global Burden of Disease Study 449–50
- glucocorticoid(s)
- antenatal 199
  - bone growth plate chondrocytes 411–12
  - brain development 198
  - cardiorenal system programming 277
  - fetal exposure to inappropriate levels
    - 198–9
  - fetal protection 196–7
  - head circumference 198–9
  - hypothalamic–pituitary–adrenal axis
    - 191–2
  - insulin resistance 216
  - IUGR 248–9
  - maternal in kidney disease 316–17
  - placental 137–8
  - prenatal stress 195
  - preterm birth risk 198
  - synthetic
    - HPA axis 197–9
    - very-low-birthweight infants 216
- glucocorticoid receptors 192
- epigenetic modifications 69
- glucose
- fetal combined oxygen deficiency 146
  - glucose tolerance testing 210
  - lipid synthesis 257
  - maternal levels and birth size 461

## 506 Index

- glucose (*cont.*)
  - metabolism
    - early malnutrition 238–9
    - embryo 53–4
    - fetal 143–4, 145, 149
  - regulation in twins 217
  - transport 135
- glucose challenge, oral 238
- glucose intolerance
  - birthweight 206–7
  - growth rate 460
  - maternal protein restriction 245
  - placental insufficiency 240
- glucose tolerance testing 210, 238
- glucose transporters (GLUTs) 135
  - placental development 149–50
- glucose-sparing muscle metabolism 17
- GLUT1 135
- glutamate 384
- glutathione-S transferase M and T genes 362
- glycogen, fetal reserves 151
- grip strength 401
- growth
  - acceleration in SGA children 207
  - catch-up 40, 226
    - endothelial dysfunction 289
  - glucocorticoid treatment in pregnancy 248–9
  - maternal protein restriction 245–6
  - skeletal 408–9
- childhood 6–7
  - cardiovascular disease risk 225–6
  - height 464
  - hip fracture 399–400, 400
- coronary heart disease 10, 226
  - magnitude of effect 9–10
- diabetes 460
  - disease association 450
  - early and adiposity 267
  - glucose intolerance 460
  - height in children 464
- infants 25
  - stress 269
- patterns 223–30
  - diabetes type 2 228–9
  - disease outcome 228–9
- placental–fetal 57
- postnatal
  - cognition 370–1
  - fetal growth relationship 123
  - restriction effect on lungs 337–8
  - prenatal 223–4
  - restriction
    - lung effects 337–8
    - maternal protein restriction 247–8
  - see also* infants, growth
- growth, fetal 6–7, 395
  - amino acid transporter system A inhibition 135–6
  - bone in utero 393–4
  - calcium maternal supplementation 111, 116
  - caloric maternal supplementation 119–20
  - cognitive dysfunction 167–8
  - coronary heart disease 8
  - developmental programming susceptibility 400–1
  - early and maternal nutrition 21–2
  - immune system 19–20
    - response 355–6
  - interventions for improvement 121–4
  - magnesium maternal supplementation 113
  - maternal anthropometry association 104–6
  - maternal constraint 40–1
  - maternal diet 106–7, 465, 477
    - calcium maternal supplementation 111, 116
    - caloric maternal supplementation 119–20
    - determinants 100–1
    - early 21–2
    - interventions 116–17
    - protein/energy supplementation 108–9
    - protein restriction 245–6
    - restriction 250
  - maternal weight gain in pregnancy 105
- patterns 223–4
- periconceptional influences 21–2
- placenta
  - function 135–6
  - size 134
- postnatal growth relationship 123
- predictors 104
- prenatal hypoxia 183–5
- pre-pregnancy weight 105
- protein/energy supplementation 116
- protein supplementation 108–9
- retardation in utero 39
- stress in pregnancy 195–6
- stroke risk 10–11
- time scale for interventions 121
- growth factors, cancer risk 421
- growth hormone (GH)
  - bone mineral density 396–7, 397
  - fetal metabolism 146–7
  - rat bone development 407–9

- SGA children 207–8
- very-low-birthweight children 214
- growth hormone secretagogue receptor (GHSR) 55
- harm, risk 477–8
- head circumference
  - allergy 356
  - glucocorticoids 198–9
  - muscle mass 403
- health
  - adult 6–7
  - determinants 447
  - respiratory 19–20
  - right to be born healthy 474
  - see also* disease; ill health
- healthy lifestyle 476
- heart
  - afterload 280–1
  - anatomy 279–80
  - ischaemia–reperfusion injury 278
  - preload 280
  - ventricular myocytes 281
  - see also* cardiovascular disease; cardiovascular system; coronary heart disease
- heavy metals 91–2
- high-altitude studies 184
  - duration of residence 184
  - hypoxia 183–5, 186
- hip fracture, childhood growth 400, 399–400
- hippocampus formation 192
- histone
  - acetylation 2–3, 65
  - covalent modification 64–5
  - methylation 65
  - modifications 93
    - abnormalities 68, 70–1
  - sumoylation 65
  - tails 64
- homeorhesis 35
- hominid evolution, predictive adaptive responses 45–6
- hormones, intrauterine manipulation 151
- human research ethics 476–7
- human rights, public health 478–9
- 11 $\beta$ -hydroxysteroid dehydrogenases 137–8
  - adipose tissue 258
  - fetal protection from glucocorticoids 196–7
  - maternal glucocorticoid effects 317
  - maternal protein restriction 249
- 5-hydroxytryptamine (5-HT) 198
- hygiene hypothesis of allergic disease 358, 358–60
- hypercholesterolaemia, maternal 300–1
  - cholesterol lowering 306
  - fetal atherosclerosis lesion formation 301–6
- hyperglycaemia
  - diabetic pregnancy 135
  - embryo metabolism 53–4
- hyperosmolality model 305
- hypertension 10–14
  - atherosclerosis-related disease 306
  - birth size 458–61
  - birthweight 458–61
  - Brenner hypothesis 313–14
  - cardiovascular disease 437
  - developmental mechanisms 13–14
  - impaired PUFA assimilation 168–9
  - low birthweight 11
  - management 442–3
  - maternal nutritional restriction
    - iron 248
    - protein 245, 277, 290–1
  - metabolic syndrome 438, 441
  - obesity role 260–1
  - placental size 11–13
  - prediction 13
  - primary prevention 441
  - renal development impairment 13
  - renin–angiotensin system 290–1
  - stroke 11
- hypertonicity, fetal 324
- hypothalamic–pituitary function
  - maternal undernutrition 439
  - obesity 438
  - osteoporosis 396–7
- hypothalamic–pituitary–adrenal (HPA) axis
  - development 191–4
  - fetal 13–14, 57, 191–200
    - endocrine gland development 150–1
    - premature activation 194–9
    - prenatal stress 195–6
    - prenatal undernutrition 196–7
  - fetal fat 257–8
  - glucocorticoids 191–2
    - synthetic 197–9
  - high-altitude studies 186
  - impaired PUFA assimilation 168–9
  - intrauterine environment sensitivity 191
  - parturition process/timing 197
  - prenatal hypoxia 185–6
  - programming 191, 198, 199–200

- hypothalamic–pituitary–adrenal (HPA) axis (*cont.*)  
 stress  
   maternal 36–7  
   responses 374  
   vascular function 291  
 hypothalamus 192–3  
 hypoxia 180  
   acute 179–82  
   adrenocortical function 185–6  
   cardiac output redistribution 186–7  
   cerebral 380  
   chronic 182–3  
   fetal  
     cardiovascular responses 180–2, 277–8  
     IUGR association with cardiovascular dysfunction 187  
     stress system stimulation 180–2  
   high-altitude studies 183–5, 186  
   ischaemia–reperfusion injury 278  
   models 382–3  
   peripheral vasoconstriction 186–7  
   placental 133  
   prenatal 178–88  
     fetal cardiovascular defence 179–83  
     fetal growth 183–5  
     HPA axis 185–6  
   risk factors 179  
 hypoxia-inducible factor 1 (HIF-1) 133
- Igf* genes 153  
*Igf2PO* gene 57  
 ill health  
   chronic 475  
   responsibility for 475  
   *see also* disease  
 immune response  
   allergic 350–1  
     postnatal influences 356–7  
   antenatal 354–6  
   fatty acids 355–6  
   fetal 352  
     growth 355–6  
   lipids 355–6  
   nutrition 355–6  
 immune system  
   environmental chemical effects 92–3  
   fetal development 169  
   fetal growth 19–20  
   function and impaired PUFA assimilation 169–71  
 immunisation avoidance 359
- immunoglobulin E (IgE)  
   amniotic fluid 353–4  
   sensitisation risk 355  
 immunoglobulin E (IgE) antibodies 357  
 immunoglobulin G (IgG)  
   amniotic fluid 353–4  
   maternal 354–5  
 immunology in pregnancy 352–4  
 imprinting *see* genetic imprinting  
 infant feeding allergy in asthma 360  
 infants  
   body mass index 18  
   body weight and adult bone mass 395–6  
   bone mineral accrual 394  
   cardiovascular disease risk 463–4  
   docosahexaenoic acid accretion 167  
   fat growth 258–9  
   growth 6–7, 25  
     adult health outcomes 224–5  
     coronary heart disease 8–9  
     promoting 225  
     protein/energy maternal supplementation 109  
     stress 269  
   nutrition 464, 467  
   weight gain 463–4  
 infection  
   brain damage 381  
     models 384–5  
   early exposure 359–60  
   preterm birth 381  
 inflammation/inflammatory response  
   allergic 361–2  
   brain damage 381  
     models 384–5  
   early development 270–1  
   endothelial cell activation 289–90  
   insulin resistance 270–1  
   metabolic syndrome 270–1  
 inflammatory agents, fetal brain 4  
 inflammatory cascade, lipopolysaccharide activation 385  
 influenza, schizophrenia risk 371, 373  
 insects, social 431–2  
 insulin  
   action and  $\beta$  cell function 235  
   deficiency in diabetes type 2 16  
   early malnutrition 238–9  
   glucose tolerance testing 210, 238  
   IGF1 correlation 208  
   maternal protein restriction 246–7

- sensitivity 211, 215, 217
- signalling 430
- insulin receptor 247–8
- insulin resistance 244–51
  - diabetes type 2 16
  - endothelial dysfunction 288
  - glucocorticoids 216
  - inflammation 270–1
  - low birthweight 17
  - maternal weight/body mass index 25
  - metabolic syndrome 16–17, 265–6
  - obesity 266–7
  - placental insufficiency 240
  - pregnancy 239
  - SGA children 209–11, 215–16
  - sheep models 250
  - size at birth 17
  - twins 216–17
  - uteroplacental insufficiency 249
  - very-low-birthweight children 215–16
- insulin-like growth factor(s) (IGFs)
  - fetal metabolism 146–7
  - prematurity 214
  - SGA children 214
- insulin-like growth factor 1 (IGF1) 137
  - bone growth plate effects 409
  - insulin correlation 208
  - rat bone development 407–9
  - SGA children 207
  - very-low-birthweight children 214
- insulin-like growth factor 2 (IGF2)
  - gene polymorphisms 403
  - kidney development 316
  - pancreas development 236–7
  - small for gestational age 208–9
  - very-low-birthweight children 214–15
- insulin-like growth factor-binding protein (IGFBPs) 137
  - small for gestational age 208–9
  - very-low-birthweight children 214
- interleukin(s) 353
  - allergic immune response 350–1
- interleukin 6 (IL6)
  - metabolic syndrome 271, 437
  - in-utero exposure 251
- interleukin 13 (IL 13) 171
- intracellular signalling, fetal 152
- intrauterine growth retardation (IUGR) 39
  - cardiovascular disease 178–9
  - cardiovascular dysfunction 187
  - causes 244
  - developing countries 456, 457
  - glucocorticoids 248–9
  - lungs
    - development 336–7
    - postnatal function 337
  - maternal anthropometry 102
    - indicators 102–3
    - measures 102
  - metabolic syndrome 268
  - neurological disorders 386
  - obesity programming 259–60
  - patterns 99
  - preterm birth and lung development 344
  - stress system 178–9, 248–9
  - trophoblast invasion 133
  - uteroplacental insufficiency 249–50
  - vascular function 290, 291
- intravascular volume, body fluid regulation 324–5
- iodine, maternal supplementation 122
- iron
  - maternal restriction 248
  - maternal supplementation 111–12
    - folate combination 113
- islets of Langerhans 235
- jaundice, neonatal 418
  - testicular cancer 420
- ketone bodies 438
  - release in pregnancy 163
- kidney
  - compensatory changes 317–18
  - development 310–11, 325
    - functional of fetal 311–12
    - hypertension 13
    - impairment 13, 313–14
  - maternal protein restriction 277
  - obesity in function impairment 260–1
  - programming 329–30
  - sodium transporters 312
  - water channels 312–13
  - see also renal entries*
- kidney disease 310
  - anaemia 316
  - glucocorticoids 316–17
  - low birthweight 314
  - maternal diabetes 315–16

## 510 Index

- kidney disease (*cont.*)
  - maternal steroids 316–17
  - maternal undernutrition 314, 315
  - protein restriction 315, 411
- lactacidaemia, fetal 146
- lactation, maternal nicotine exposure 342–3
- lactogen, placental 150
- Langley Evans model of fetal protein insufficiency 407–12
- large offspring syndrome (LOS) 51
- late offspring syndrome 22
- lead neurotoxicity 92
- learning, spatial 372
- leptin 211–12
  - fetal sensitivity 258
- life span 426–32
  - controlling factors 429–30
  - evolutionary factors 429
  - insulin signalling 430
  - reactive oxygen species 430
  - variability 432
- lifestyle, maternal
  - healthy 476
  - neonatal bone mineral 397–9
- lipids
  - circulating 161–2
  - fetal development 159–60
  - immune ontogeny 355–6
  - membrane 160
  - metabolism 15, 159–71
    - maternal during pregnancy 162–5
    - pregnancy 161–2
  - peroxidation 303
- lipopolysaccharide 384–5
  - exposure 359
  - inflammatory cascade 385
  - neurodegenerative disease 90–1
  - Parkinson's disease 90–1
- lipoprotein lipase, placental 166
- lipoproteins 161
- liver programming 440
- locus coeruleus–noradrenaline autonomic complex (LC/NA) 178
- longevity 3
- low birthweight 2
  - adult disease 6, 25
  - atherosclerosis-related disease 306
  - burden 25–6
  - children growing big 458–9
  - coronary heart disease risk 6
  - developing countries 458–9
  - diabetes mellitus type 2 risk 6
  - endothelial dysfunction 281–2, 288–9
  - epidemiology 100
  - glucose intolerance 206–7
  - hypertension 11
  - incidence 99
  - insulin resistance 17
  - kidney disease 314
  - maternal anthropometry 101–2, 104
    - indicators 103
  - maternal body weight 101
  - maternal nutrition 98–9, 118
    - as determinant 99–100
    - interventions 122–3
  - maternal smoking 100
  - mood disorders 20
  - stress 269
  - syndrome X 206–7
  - vascular endothelial dysfunction 14–15
  - vascular structure/function 14
- low-density lipoprotein (LDL) 160
  - oxidation 301–2, 303–4
  - pregnancy 163
- lung(s)
  - hypoxaemia 339
  - maternal smoking 340–3, 362–3
  - maturation 336
  - nutritional restriction 339
  - postnatal function 337
  - postnatal growth/nutrition restriction 337–8
  - vitamin A deficiency 363
  - volume and maternal smoking 341
- lung development 3, 19, 336–44
  - IUGR 336–7
  - liquid secretion 338
  - nicotine 340, 342, 341–2, 343
  - nutrition impairment 338–40
  - preterm birth 337, 343–4
    - with IUGR 344
  - SGA babies 336–7
  - undernutrition 336–40
- lung disease, chronic 343
- magnesium, maternal supplementation 113
- malnutrition
  - early and effects on pancreas 235–8

- diabetes type 1 susceptibility 240
- diabetes type 2 238–9
- glucose metabolism 238–9
- prenatal protein and impaired learning 372–3
- mammary glands
  - environmental toxin-induced developmental delay 84
  - mass 418–19
  - see also* breast cancer
- maneb 89–90
- p38MAP kinase 133–4
- maternal influences 33–4
  - body composition 24–5
  - fetal growth 21–2
    - constraint 40–1
  - offspring health/development 20–1
  - placental size 23–4
  - size 24–5
  - weight/body mass index and insulin resistance 25
- melanocortin-type 4 receptor (MC4-R) 260
- menarche, age at 120–1
- mental health 20
- mercury 91–2
- mesonephros 310–11
- metabolic syndrome 265–71
  - behavioural programming 270
  - birthweight 266
  - body composition 269–70
  - clinical syndromes 441
  - developmental origins 265–7
  - diabetes type 2 441
  - dyslipidaemia 438, 441
  - early development 267–8
  - hypertension 438, 441
  - inflammation 270–1
  - insulin resistance 16–17, 265–6
  - IUGR 268
  - management 442–3
  - maternal fat feeding 291–2
  - maternal protein restriction 245
  - maternal undernutrition 268
  - obesity 266–7, 271, 437
  - pathophysiology 437–8
  - primary prevention 441–2
  - susceptibility 438–9
  - transgenerational transmission of risk factors 292
- metabolism, fetal 143–54
  - amino acids 144–5
  - cellular mechanisms 151–2
  - combined oxygen/substrate deficiency 146
  - endocrine regulation 146–7
  - enzyme activities 152
  - glucose 143–4, 145
  - glucose transporters 149–50
  - hormone exposure duration 147
  - hypoxaemia 145–6
    - combined substrate deficiency 146
    - placental development 149–50
  - molecular mechanisms 152–3
  - nutritional regulation 143
  - oxygen deprivation 145–6
  - protein synthesis 152
  - substrate availability 143–5
- metanephros 310, 311
- methoxychlor 84–5
  - prostate effects 86
  - reproductive effects in males 87
  - transgenerational effects 87
- methyl-aminoisobutyric acid 150
- micronutrient deficiencies, maternal in developing countries
  - 464–5
- milk, allergy to cows' 360
- mineralocorticoid receptors 192
- mitochondria
  - developmental programming component 75–9
  - dysfunction 76–7
  - fetal oxidative function 152
  - qualities 77–8
  - stress-induced changes 76
- mitochondrial DNA *see* mtDNA
- mood disorders 20
- morphogenesis 432
- Morris water maze 372
- mortality 475
- mothers
  - relationship with fetus 473–4
  - role of 473–4
- mtDNA 75–6, 429
  - developmental programming 78–9
  - environmental factor sensitivity 77–8
  - mutations 77–8
    - stress-induced 78–9
  - pre-implantation 77–8
  - replication during human pre-implantation development 78
  - synthesis 77–8
- mTOR signalling 55
- muscle, skeletal
  - glucose-sparing metabolism 17
  - mass 19, 403



## 512 Index

- muscle, skeletal (*cont.*)
  - maternal protein restriction 247
  - strength 19
- musculoskeletal system 392–403
  - ageing 392–3
  - health 18–19
  - sarcopenia 401–3
  - see also* osteoporosis; skeleton
- Mycobacterium vaccae* vaccine 359
- myocardial infarction 300
- natural selection, ageing 427
- nDNA 75–6, 79
- neonates
  - antibody response 352
  - behaviour and stress in pregnancy 195–6
  - bone mineral density
    - maternal lifestyle/nutrition 398, 397–8, 399
    - maternal smoking 399
  - environment mismatch with fetal 41
  - fat thermoregulation role 256
- nephrogenesis 314
- nephron number 317–18
  - fetal programming 440
- nervous system
  - development 379
  - environmental agents in disease/dysfunction 89–92
- Netherton syndrome 361–2
- neural processes, growth compromise 383
- neural tube defects, periconceptional folate 112–13, 122
- neurodegenerative disease, environmental chemicals
  - 89–91
- neuroendocrine development, programming 198
- neuroendocrine signalling, maternal–fetal 57
- neurogenesis, stress 374
- neurogenin-3 gene 235
- neurological disorders 379–88
  - animal studies 381–3
  - brain function alteration in prenatal compromise
    - 386–7
  - factors affecting normal brain development 380–1
  - IUGR 386
  - preterm birth 381
  - therapeutic intervention 387
  - very low birthweight 386
- neurons
  - hypoxic insults 383
  - hypoxic–ischaemic injury 380
- neurotrophin brain-derived neurotrophic factor (BDNF) 384
- nicotine
  - lung development 340, 342, 341–2, 343
  - obesity association 89
- nitrate stress, placenta 133–4
- nitric oxide 133–4, 380
  - atherogenesis 303
  - hypoxia 181–3
  - shear stress 288
  - vascular damage 302
  - vascular endothelial production 287–8
- nitric oxide synthase (NOS) gene 288
- nitrotyrosine residues, pre-eclampsia 133–4
- NMDA receptors 92
- Notch signalling 235
- nuclear DNA *see* nDNA
- nuclear factor (NF)- $\kappa$ B 384
- nuclear receptors 437–8
- nucleosome remodelling 64
  - defects 70–1
- nutrition
  - behaviour 371–5
  - bone development 406–7
  - cognitive function 371–5
  - developing countries 456–7
  - energy mismatch 46–7
  - ethics of supplementation 478
  - fetal 118
    - coronary artery disease 276–7
    - immune response 355–6
    - twins 217
  - infants 464, 467
    - blood pressure 451
  - intrauterine manipulation 151
  - Langley-Evans model of fetal protein insufficiency 407–12
  - lungs
    - development effects of impairment 338–40
    - postnatal restriction effect 337–8
  - periconceptional 51
  - predictive adaptive response to stimulus 46
  - prematurity 216
  - regulation and fetal metabolism 143
  - signals 45
  - transgenerational reproductive performance 23
  - see also* food; malnutrition; undernutrition
- nutrition, maternal 24–5, 98
  - advice in pregnancy 108
  - calories
    - restriction 244–5
  - supplementation 119–20

- cardiovascular disease 465–6
- developing countries 464–6
  - public health policy 466
- development of offspring 21
- embryonic perception 51–3
- endocrine regulation of fetal metabolism 146–7
- fetal growth 465
  - determinants 100–1
  - early 21–2
- fetal programming 466
- food-based supplements 122
- health of offspring 21
- improvement 25–6
- influences 124
- intergenerational influences 120–1
- intervention targeting 122–4
- large-scale interventions 121–2
- low birthweight 98–9, 118
  - determinant 99–100
- mitochondrial function 76–7
- mood disorders 20
- mtDNA alterations 76–7
- neonatal bone mineral density 397–8, 398, 399
- offspring phenotype modulation 69
- periconceptual 22, 57, 121
  - preterm delivery 124
- placental development 149–50
- prematurity 123–4
  - with undernutrition 35
- public health policy in developing countries 466
- restriction 250
  - fetal adiposity 257
  - lung effects 339
  - vascular function 291–2
- status as low-birthweight determinant 99–100
- supplementation 117, 478
- timing of interventions 118–20
- transgenerational effects 22–3, 43
- see also* diet, maternal; malnutrition; protein, maternal restriction; undernutrition, maternal
- obesity 255–62
  - adiposity rebound 18
  - asthma risk 363
  - bisphenol A 88–9
  - childhood epidemic 3–4
  - developing countries 467
  - diethylstilbestrol 88, 89
  - environmental chemicals 88–9
  - environmental oestrogens 88–9
  - epidemic 88
  - estradiol 88
  - fetal programming 255–6, 466
  - genistein 88, 89
  - high fat feeding 251
  - hypertension 260–1
  - hypothalamic–pituitary function 438
  - insulin resistance 266–7
  - IUGR 259–60
  - kidney function impairment 260–1
  - maternal protein/energy restriction 110
  - metabolic syndrome 266–7, 271, 437
  - nicotine 89
  - pandemic 255
  - primary prevention 441–2
  - programming 439–40
  - sympathetic nervous system 438
- oestradiol
  - obesity 88
  - prostate effects 86
- oestrogens
  - breast cancer
    - intrauterine exposure 416, 417, 418
    - risk 421
- environmental 86–7
  - obesity 88–9
- fertility 86–7
- genotoxicity 421
- prostate development 85–6
- testis function 86–7
- offspring, maternal influences on health/development 20–1
- 1, 25 (OH)<sub>2</sub> vitamin D<sub>3</sub> 393–4
  - rat bone development 407–9
- osmolality
  - body fluid regulation 324–5
  - maternal plasma 323, 324
- osmoregulatory mechanisms, fetal 324–5
  - programming 325–8
- ossification, endochondral 393–4
- osteoporosis 18–19, 406
  - ageing 428
  - developmental origins 393–4
  - developmental plasticity 400–1
  - fetal programming 395–401
  - fractures 392–3, 395–401
  - hypothalamic–pituitary function 396–7
  - prenatal events 1–2
- oxidation, atherogenesis 301–2

## 514 Index

- oxidative stress, placental 133–4
- oxidative switch, placental 133
- oxygen, fetal deprivation 145–6
  - combined substrate deficiency 146
  - placental development 149–50
- P13-kinase activation 247
- p53* gene 153
- pancreas, endocrine 233–41
  - amino acids 236–7
  - development 234, 233–4, 235
  - early malnutrition 235–8
  - maternal diabetes effects on development 237
  - maternal protein restriction 246
  - programming 440
  - transcription factors 235
  - transgenerational programming 239–40
  - vascular development 236
- paraquat 89–90
- parathyroid hormone-related protein (PTHrP) 393–4
- paraventricular nucleus 192–3
- parental imprinting 66–7
- parent-of-origin imprinting 93
- parity, breast cancer 416–17
- Parkinson's disease
  - environmental chemicals 89–91
  - lipopolysaccharide 90–1
- PDX1 transcription factor 249
- peptide hormones, placental 136–7
- periconceptual factors, fetal growth 21–2
- periconceptual period 51
  - nutrition 51
- peripheral vasoconstriction, hypoxia 186–7
- peroxisome proliferator-activated receptors (PPARs) 136, 437–8
  - see also* PPAR $\gamma$
- pH 4 lipase 136
- phenotype
  - alteration after fertilisation 78
  - development 34
  - offspring modulation 69
  - 'thin-fat' Indian baby 461–3
- phenotypic outcomes 33
- phospholipase C 55
- physical activity, obesity 442
- pituitary gland 193
- placenta 130–9
  - amino acid transport 135–6
  - angiogenesis 134–5
  - angiogenic factors 134
  - barrier function 135–6
  - blood flow 131–5
  - development 131, 149–50
  - endocrine function 136–8
  - fatty acid transport 136
  - fetal growth 135–6
  - fetal programming 130, 131, 131, 132, 134–5, 136–8
    - critical periods 139
  - glucocorticoids 137–8
  - growth 23–4, 131
    - regulation 131–5
  - hormones 150
    - cancer risk 421
  - hypoxia 133
  - imprinted genes 138
  - infections 381
  - nutrative stress 133–4
  - nutrients
    - consumption 150
    - exchange 277
  - oxidative stress 133–4
  - oxidative tension 133
  - peptide hormones 136–7
  - size
    - birthweight 11–13
    - fetal growth 134
    - hypertension 11–13
    - maternal influences 23–4
  - transfer capabilities 23–4
  - transport function 135–6
  - vascular development 134–5
  - villous 133
    - vascular development 134
  - weight and coronary heart disease 8
- placental insufficiency
  - brain development 4
  - brain hypoxic–ischaemic injury 383
  - glucose intolerance 240
  - insulin resistance 240
  - kidney disease 314
- placental–fetal growth 57
- plasma
  - hypotonicity in pregnancy 324
  - volume expansion in pregnancy 323–4
- plasminogen activator inhibitor type 1 437
- polycyclic biphenols (PCBs) 91
- polycystic ovary syndrome (PCOS) 85
  - SGA children 212
- poly(ADP-ribose) polymerase 1 (PARP1) 429–30

- polyunsaturated fatty acids (PUFAs)  
   atopy association 170–1  
   blood pressure effects of impaired assimilation 168–9  
   fetal development 166–71  
   immune function effects of impaired assimilation 169–71
- poverty 475, 478
- PPAR $\gamma$   
   fat growth 258  
   placental 136
- PPAR $\gamma$  gene  
   diabetes type 2 association 230, 229–30  
   polymorphisms 39–40
- predictive adaptive responses (PARs) 36–7, 38, 42  
   accuracy 37, 44–5  
   characteristics 36  
   fetal phenotype 46  
   health consequences 46  
   hominid evolution 45–6  
   interventional strategies 46  
   maternal fat feeding 293  
   model 44  
   nutritional stimulus 46  
   programming 41–3  
   survival advantage 41–3
- pre-eclampsia  
   breast cancer 417  
   nitrotyrosine residues 133–4  
   trophoblast invasion 133
- pregnancy  
   adipose stores 162–3  
   adolescence 465  
   allergen exposure 354–5  
   antibiotic use 358  
   anxiety 195–6  
   calcium supplementation 111, 116  
   calories  
     maternal restriction 244–5  
     maternal supplementation 119–20  
   C-reactive protein 271  
   cytokines 271  
   dexamethasone treatment 249  
     hypertension in offspring 277  
   electrolyte homeostasis 323–4  
   energy  
     maternal supplementation 108–9, 121  
     restriction 110  
     use 105–6  
   fish-oil supplementation 113–14  
   fluid homeostasis 323–4  
   folate maternal supplementation 112–13  
   high-fat feeding 251  
   immune function 169  
   immunology 352–4  
   insulin resistance 239  
   iron  
     maternal restriction 248  
     maternal supplementation 111–12  
   iron/folate combination maternal supplementation 113  
   lipid metabolism 161–5  
   magnesium supplementation 113  
   maternal diet 106–7  
     global restriction and vascular function 291–2  
   maternal fat feeding 291–2  
     endothelial dysfunction 293  
   maternal protein restriction 245–8, 250  
     endothelial dysfunction 292  
     kidney abnormalities 277  
     vascular function 290–1  
   metabolic expenditure 105–6  
   nutritional advice 108  
   nutritional interventions  
     large-scale 121–2  
     timing 118–20  
   offspring of malnourished mothers 239–40  
   outcome and maternal anthropometry 104  
   plasma  
     hypotonicity 324  
     volume expansion 323–4  
   protein supplementation 108–9, 121  
     high level 110  
     isocaloric 109  
   protein/energy supplementation 116  
   salt restriction 110–11  
   stress 195–6  
   surveillance of women 474  
   twin and breast cancer risk 417–18  
   vitamin supplementation 115–16  
   zinc supplementation 114–15  
   *see also* protein, maternal restriction; undernutrition, maternal
- pre-implantation, mtDNA replication during development 78
- prematurity/preterm birth 100, 206–7  
   arachidonic acid supplementation of infant formula 170  
   brain 5  
   breast cancer 418  
     risk 418

## 516 Index

- prematurity/preterm birth (*cont.*)  
   docosahexaenoic acid  
     accretion 167  
     supplementation of infant formula 170  
 HPA axis hyperactivity 197  
 IGFs 214  
 intrauterine infection/inflammation 381  
 IUGR 344  
 lung development 337, 343–4  
 maternal anthropometry 102  
   indicators 103–4  
 maternal nutrition 123–4, 216  
   impairment 337  
   protein malnourishment 216  
   supplementation 117  
   undernutrition 35  
 maternal pre-pregnancy weight 103–4, 105  
 metabolic programming 215  
 neurological disorders 381  
   models 385–6  
   risk and glucocorticoid use 198  
   very low birthweight 212–16  
 prenatal events 1–2  
 prepulse inhibition of startle response 386–7  
*Pro12Pro* genotype 229–30  
 probiotics 358–9  
 progesterone 150  
 programming *see* fetal programming  
 pronephros 310  
 prostate  
   dioxins 85–6  
   environmental oestrogens 85–6  
 prostate cancer 420–1  
   birthweight 420–1  
   mechanisms 421–2  
   perinatal characteristics 421  
 protein  
   fetal synthesis 152  
   high level supplementation 110  
   Langley-Evans model of fetal insufficiency  
     407–12  
   malnourishment in prematurity 216  
   maternal intake 24  
   maternal restriction 54–5, 110, 245–8, 250  
     adult bone mass 412  
     bone mineral density 409  
     endothelial dysfunction 292  
     growth plate structure 6, 409–12  
     hypertension 277, 290–1  
   impaired learning 372–3  
   kidney disease 315, 411  
   pancreatic islets 241  
   rat bone marrow stromal cells 407–9  
   social behaviour 374  
   vascular function 290–1  
 maternal supplementation 108–9, 116, 121  
   fetal growth reduction 464  
   isocaloric 109  
   maternal synthesis 25  
 protein kinase C 55  
 public health 446–53  
   animal models 448  
   causality 448–9  
   clinical studies 451  
   cohort studies 447–8, 450  
   definition 446  
   duty to be well 475–6  
   ethics 478–9  
   evidence  
     application 449–51  
     base 446–9  
   exposure information 448  
   health lifestyle 476  
   human rights 478–9  
   interventions 451–3  
     timing 452–3  
   policy  
     developing countries 466–7  
     development 450–1  
   research context 450–1  
   surveillance of pregnant women 474  
   targeted approach 451–2  
   whole population approach 451–2  
   public health policy 3  
 radiation, in-utero exposure 415  
 reactive oxygen species (ROS) 380  
   ageing 428–9  
   lifespan 430  
 renal body fluids 440  
 renal function 310–19  
   *see also* kidney  
 renal growth, fetal 13  
 renin 13  
 renin–angiotensin system 13, 312, 318  
   electrolyte homeostasis 323  
   fluid homeostasis 323  
   hypertension 290–1

- kidney development 325
- programming 328, 329–30
- renin–angiotensin–aldosterone system 438
- reproductive effort 431
- reproductive performance, nutritional transgenerational effects 23
- reproductive toxicity, environmental agents
  - female effects 83–5
  - male effects 85–7
- resistin, metabolic syndrome 437
- respiratory health 19–20
- respiratory muscle function, undernutrition 337–8
- respiratory syncytial virus 359–60
- retinoic acid 316
- rickets 395
- right to be born healthy 474
- risky persona 475–6
- salt restriction in pregnancy 110–11
- sarcopenia 401–3
- schizophrenia 20, 379
  - early neurodevelopmental hypothesis 383–4, 386–7
  - influenza 371, 373
  - risk factors 371
  - ventriculomegaly 383
- serotonergic system 198
- shear forces, cardiovascular system 279
- shear stress 288
- short stature
  - SGA children 207
  - very-low-birthweight children 213
- signal transduction 55
- skeleton
  - development 406–13
  - fetal 393
  - function 407–12
  - maturational delay 409
  - normal growth 393–4
  - programming 400, 407–12
- small for gestational age (SGA) 206–12
  - adrenal axis 212
  - auxological characteristics 207–9
  - diabetes type 2 209–11
  - endocrine axis 208, 207–8, 209
  - growth acceleration 207
  - growth hormone 207–8
  - IGF1 207, 208–9, 214
  - IGF2 208–9, 214
  - insulin resistance 209–11, 215–16
  - insulin-like growth factor-binding protein 208–9
  - lung development 336–7
  - maternal nutrition supplementation 117
  - metabolic axis 209–12
  - reproductive axis 212
  - short stature 207
  - syndrome X 209
- smoking
  - breast cancer risk 418
  - maternal 19
    - fetal lung development 340–3
    - in pregnancy 89
    - low birthweight 100
    - lung function 362–3
    - neonatal bone mineral density 399
  - testicular cancer 420
- social behaviour 374
  - maternal protein restriction 374
- social insects 431–2
- socioeconomic factors, fetal programming 473
- sodium channels 318
- sodium transporters 312, 318
- somatic cell nuclear cloning (SCNC) 67–8
- somatic cells
  - epigenetic markers 68
  - maintenance investment 427
- startle response, prepulse inhibition 386–7
- steroids, maternal 316–17
- stress 191
  - behavioural response 269
  - epigenetic factors 374
  - glucocorticoid receptor epigenetic modifications 69
  - infant growth 269
  - IUGR 248–9
  - low birthweight 269
  - mitochondrial changes 76
  - mtDNA mutation 78–9
  - neurogenesis 374
  - pregnancy 195–6
    - offspring behaviour 373–4
  - prenatal 195–6
  - system
    - hypoxia stimulation 180–2
    - IUGR 178–9
- stroke 10–11
  - fetal growth 10–11
  - hypertension 11
- superoxide 133–4
- supraoptic nucleus 192–3

## 518 Index

- swallowing, fetal 324–5, 353
- sympathetic nervous system
  - obesity 438
  - programming 328–9
- synaptogenesis 379
  - compromised 383
- syndrome X
  - low birthweight 206–7
  - SGA children 209
- T cells
  - allergic immune response 350–1
  - fetal 353
  - pregnancy 169
- T-helper 1 cells 359
- T-helper cells 351
  - immune stimulators 353
  - postnatal allergic immune response 356–7
- taurine 237, 240
  - supplementation 241, 246
- telomere damage 428–9
- teratogenesis 34–5
- testicular cancer 419–20
  - birth characteristics 420
  - birth cohort phenomenon 419
  - cryptorchidism 419
  - fertility 420
  - histopathological types 419–20
  - incidence 419
  - mechanisms 421–2
  - perinatal characteristics 421
  - smoking 420
- testis function, oestrogens 86–7
- thermogenesis, shivering 256
- 'thin-fat' Indian baby 461–3
- thrifty genotype hypothesis 38–9, 436
- thrifty phenotype hypothesis 35–6, 39, 209, 436, 456
- toll-like receptors (TLRs) 384, 385
- trade-offs, biological 35
  - developmental 39
- transcription factors
  - fetal 152–3
  - pancreas 235
- transcriptional silencing, methylation-mediated 63
- transforming growth factor  $\beta$  (TGF $\beta$ ) 361
- triacylglycerol 161–2
  - plasma concentration in pregnancy 163
- trophoblast invasion 131–3
- tumour necrosis factor  $\alpha$  (TNF $\alpha$ ) 271, 437
- tumour-suppressor gene silencing 71–2
- twins
  - birthweight 216–17
  - breast cancer 417–18
  - metabolic axis 216–17
- umbilical circulation 131
- uncoupling protein 1 (UCP1) 256, 257, 258
- undernutrition
  - airway growth 339–40
  - alveolar formation 339
  - fetal in cardiovascular disease development 439
  - postnatal effect on lungs 337–8
  - respiratory muscle function 337–8
- undernutrition, maternal
  - body size 400–1
  - cardiovascular disease development risk 439
  - fetal HPA axis 196–7
  - hormonal effects 146–7
  - hypothalamus–pituitary axis 439
  - kidney disease 314, 315
  - lung development 336–40
  - metabolic syndrome 268
  - placental development 149–50
- ureteric bud 311
- uterine artery ligation 249–50
- uteroplacental circulation 131–3
- uteroplacental insufficiency 249–50
- vascular compliance 290, 294
- vascular dysfunction 286–95
- vascular endothelial cell activation 289–90, 293–4
- vascular endothelial dysfunction 14–15, 281–2
  - animal models 292–4
  - atherogenesis 300
  - baroreceptor responses 294–5
  - diabetes type 2 288
  - insulin resistance 288
  - low birthweight 281–2
  - maternal fat feeding 293
  - sympathetic activity 294–5
- vascular endothelium 287–8
  - activation 287
  - function 288–9
  - oxidation-sensitive mechanisms in wall 304
- vascular function
  - developmental programming 290–5
  - environmental influence during development 287

IUGR 291	vitamin D
maternal fat feeding 291–2	maternal insufficiency 18–19
maternal global dietary restriction 291–2	maternal supplementation 115, 356
maternal protein restriction 290–1	postnatal supplementation 356
vasoactive agents 287–8	<i>see also</i> 1, 25 (OH) <sub>2</sub> vitamin D <sub>3</sub>
ventriculomegaly 383	vitamin D receptor
very low birthweight (VLBW) 206–7	bone mineral density 396
auxological characteristics 212–14	genotype 396
behavioural dysfunction 371	vitamin E, maternal supplementation 115
endocrine axis 214–15	
insulin resistance 215–16	water channels 312–13
metabolic axis 215–16	weaning 360
neurological injury 386	women
prematurity 212–16	autonomy 474
very-low-density lipoprotein (VLDL) 163	duty to be well 476
vinclozolin, sexual differentiation effects 86–7	social justice 475
vitamin(s), maternal supplementation 115–16	targeting young 477–8
vitamin A	
deficiency	X chromosome inactivation 67
kidney disease 316	xenoestrogens, female effects 83–5
lung function 363	<i>XIST</i> gene 67
maternal supplementation 115–16	
vitamin C, maternal supplementation 115	zinc, maternal supplementation 114–15, 123